Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Ann Rheum Dis. 2014 May 9;74(1):190–195. doi: 10.1136/annrheumdis-2014-205233

Figure 2.

Figure 2

(A) Absolute plasmablast count (/mL) at baseline (month 0) and following rituximab (RTX) infusions. Each line represents a different patient (n=12 patients). (B) Absolute IgG4+ plasmablast count (/mL) at baseline (month 0) and following RTX infusions. Each line represents a different patient (n=6 patients). The same colour is used for these six patients as in figure 2(A).